ATE227737T1 - Gebrauch einer pharmazeutischen zusammensetzung, enthaltend ein appetitzügelndes peptid - Google Patents

Gebrauch einer pharmazeutischen zusammensetzung, enthaltend ein appetitzügelndes peptid

Info

Publication number
ATE227737T1
ATE227737T1 AT97905000T AT97905000T ATE227737T1 AT E227737 T1 ATE227737 T1 AT E227737T1 AT 97905000 T AT97905000 T AT 97905000T AT 97905000 T AT97905000 T AT 97905000T AT E227737 T1 ATE227737 T1 AT E227737T1
Authority
AT
Austria
Prior art keywords
peptide
pharmaceutical composition
composition containing
appetite suppressing
appetite
Prior art date
Application number
AT97905000T
Other languages
English (en)
Inventor
Lars Thim
Birgitte Schjellerup Wulff
Martin Edward Judge
Ole Dragsbak Madsen
Jens Juul Holst
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26063575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE227737(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE227737T1 publication Critical patent/ATE227737T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT97905000T 1996-03-01 1997-02-27 Gebrauch einer pharmazeutischen zusammensetzung, enthaltend ein appetitzügelndes peptid ATE227737T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK23196 1996-03-01
DK23096 1996-03-01
PCT/DK1997/000086 WO1997031943A1 (en) 1996-03-01 1997-02-27 Use of a pharmaceutical composition comprising an appetite-suppressing peptide

Publications (1)

Publication Number Publication Date
ATE227737T1 true ATE227737T1 (de) 2002-11-15

Family

ID=26063575

Family Applications (3)

Application Number Title Priority Date Filing Date
AT01122701T ATE395359T1 (de) 1996-03-01 1997-02-27 Peptid zur appetitzügelung, dessen zusammensetzungen und verwendung
AT97905000T ATE227737T1 (de) 1996-03-01 1997-02-27 Gebrauch einer pharmazeutischen zusammensetzung, enthaltend ein appetitzügelndes peptid
AT08103786T ATE505485T1 (de) 1996-03-01 1997-02-27 Appetithemmendes peptid, zusammensetzung und verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01122701T ATE395359T1 (de) 1996-03-01 1997-02-27 Peptid zur appetitzügelung, dessen zusammensetzungen und verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT08103786T ATE505485T1 (de) 1996-03-01 1997-02-27 Appetithemmendes peptid, zusammensetzung und verwendung

Country Status (22)

Country Link
EP (4) EP2295453A3 (de)
JP (1) JP4064460B2 (de)
KR (1) KR100611130B1 (de)
CN (1) CN1112367C (de)
AT (3) ATE395359T1 (de)
AU (1) AU710818B2 (de)
BR (1) BR9707807A (de)
CA (1) CA2246733C (de)
CY (2) CY2619B2 (de)
CZ (1) CZ297338B6 (de)
DE (3) DE69738695D1 (de)
DK (2) DK1975177T3 (de)
ES (3) ES2306685T3 (de)
FR (1) FR13C0009I2 (de)
HU (1) HU229234B1 (de)
IL (1) IL125805A0 (de)
NO (2) NO323043B1 (de)
PL (1) PL187095B1 (de)
PT (1) PT1975177E (de)
RU (1) RU2197261C2 (de)
UA (1) UA70283C2 (de)
WO (1) WO1997031943A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
CA2246733C (en) * 1996-03-01 2010-07-20 Novo Nordisk A/S Use of a pharmaceutical composition comprising an appetite-suppressing peptide
EP1231219B1 (de) 1996-04-12 2010-08-25 1149336 Ontario Inc. Dem Glukagon ähnliches Peptid-2
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ES2290799T3 (es) * 1996-11-12 2008-02-16 Novo Nordisk A/S Uso de peptidos glp-1.
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
ATE273996T1 (de) * 1997-09-12 2004-09-15 Pharis Biotec Gmbh Zusammensetzung zur therapie von diabetes mellitus und fettsucht
EP1049486A4 (de) 1997-12-05 2006-01-04 Lilly Co Eli Glp-1 formulierungen
JP2002508162A (ja) * 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
AU2610899A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
JP2002504527A (ja) * 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
WO1999047161A1 (en) * 1998-03-19 1999-09-23 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
ES2310192T3 (es) * 2000-09-18 2009-01-01 Sanos Bioscience A/S Uso de peptidos glp-2.
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2002043709A1 (fr) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Procede de production d'une preparation contenant une substance bioactive
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
EP1592471B1 (de) 2003-02-04 2011-03-23 Novo Nordisk A/S Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
ES2397241T3 (es) 2004-01-21 2013-03-05 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
SI1729795T1 (sl) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albuminski fuzijski proteini
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
KR101040415B1 (ko) * 2004-04-15 2011-06-09 알케르메스,인코포레이티드 중합체 기재 지속적 방출 방법
EP1758575A1 (de) 2004-06-11 2007-03-07 Novo Nordisk A/S Bekämpfung von arzneimittel-induzierter fettleibigkeit unter verwendung von glp-1-agonisten
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ATE498631T1 (de) † 2005-05-04 2011-03-15 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
ES2336575T3 (es) 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
ATE444741T1 (de) 2006-05-10 2009-10-15 Biocompatibles Uk Ltd Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
EP2363112B8 (de) 2006-08-09 2018-11-21 Intarcia Therapeutics, Inc. Osmotisches Verabreichungssystem mit KOLBENANORDNUNG
CN101573376B (zh) 2006-11-08 2013-11-06 西兰制药公司 选择性胰高血糖素样肽-2（glp-2）类似物
EP2157967B1 (de) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspensionsformulierungen insulinotroper peptide und ihre verwendung
CA2694863A1 (en) * 2007-08-16 2009-02-19 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
AU2010298733B2 (en) 2009-09-28 2014-10-09 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
WO2014010586A1 (ja) 2012-07-10 2014-01-16 武田薬品工業株式会社 注射用製剤
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR101576126B1 (ko) 2014-12-29 2015-12-11 부경대학교 산학협력단 αＡＬ１４ 펩타이드를 유효성분으로 함유하는 신규 비만 예방 및 치료용 약학적 조성물
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
EP3302354B1 (de) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Systeme zum einsetzen eines implantats
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
RU2753193C2 (ru) 2016-12-09 2021-08-12 Зилэнд Фарма А/С Ацилированные двойные агонисты glp-1/glp-2
IL307966A (en) 2017-01-03 2023-12-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
AU2020268087A1 (en) * 2019-05-06 2021-11-25 The University Of Sydney Methods for the fractionation of proteins

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
EP0116201B1 (de) 1983-01-12 1992-04-22 Chiron Corporation Sekretorische Expression in Eukaryoten
WO1984004330A1 (en) 1983-04-22 1984-11-08 Amgen Secretion of exogenous polypeptides from yeast
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
JP2523562B2 (ja) 1985-10-25 1996-08-14 ザイモジェネティックス インコーポレーテッド 外来タンパク質を分泌することを目的としたｂａｒ１の使用法
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
ATE170557T1 (de) 1987-07-24 1998-09-15 Chiron Corp Züchtung von insektenzellen mit airlift-reaktoren
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
WO1990005783A1 (en) 1988-11-18 1990-05-31 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
CA2246733C (en) * 1996-03-01 2010-07-20 Novo Nordisk A/S Use of a pharmaceutical composition comprising an appetite-suppressing peptide

Also Published As

Publication number Publication date
NO984005L (no) 1998-08-31
EP1231218B1 (de) 2008-05-14
WO1997031943A1 (en) 1997-09-04
EP1975177A1 (de) 2008-10-01
DE69740176D1 (de) 2011-05-26
FR13C0009I1 (de) 2013-03-22
IL125805A0 (en) 1999-04-11
HUP9902670A3 (en) 2000-02-28
DE69738695D1 (de) 2008-06-26
FR13C0009I2 (fr) 2013-08-16
KR100611130B1 (ko) 2006-11-30
NO323043B1 (no) 2006-12-27
ATE395359T1 (de) 2008-05-15
AU1871597A (en) 1997-09-16
EP0891378B1 (de) 2002-11-13
EP2295453A3 (de) 2011-03-30
CN1112367C (zh) 2003-06-25
CZ297338B6 (cs) 2006-11-15
AU710818B2 (en) 1999-09-30
ES2306685T3 (es) 2008-11-16
DE69717092D1 (de) 2002-12-19
RU2197261C2 (ru) 2003-01-27
PL328732A1 (en) 1999-02-15
EP0891378A1 (de) 1999-01-20
PT1975177E (pt) 2011-07-26
NO2013006I1 (no) 2013-04-02
KR19990087439A (ko) 1999-12-27
EP1975177B1 (de) 2011-04-13
DK1975177T3 (da) 2011-07-25
CN1215405A (zh) 1999-04-28
CY2013008I2 (el) 2015-08-05
EP1231218A3 (de) 2002-10-30
DK0891378T3 (da) 2003-01-06
CA2246733A1 (en) 1997-09-04
CY2013008I1 (el) 2015-08-05
CA2246733C (en) 2010-07-20
ES2187756T3 (es) 2003-06-16
EP1231218A2 (de) 2002-08-14
CY2619B2 (de) 2013-03-13
ATE505485T1 (de) 2011-04-15
BR9707807A (pt) 1999-07-27
JP2000505460A (ja) 2000-05-09
ES2364705T3 (es) 2011-09-12
CZ273698A3 (cs) 1998-12-16
DE69717092T2 (de) 2003-07-24
NO984005D0 (no) 1998-08-31
JP4064460B2 (ja) 2008-03-19
EP2295453A2 (de) 2011-03-16
UA70283C2 (en) 2004-10-15
NO2013006I2 (de) 2013-03-12
PL187095B1 (pl) 2004-05-31
HU229234B1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
ATE227737T1 (de) Gebrauch einer pharmazeutischen zusammensetzung, enthaltend ein appetitzügelndes peptid
DK1094834T3 (da) Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf
NO992557D0 (no) Bruk av GLP-1-analoger og derivater administrert perifert i regulering av fedme
EP1529534A3 (de) Verwendung von GLP-1 Peptiden
DK1171465T3 (da) Analoger til gastroinhibitorisk peptid og deres anvendelse til behandling af diabetes
CA2073856A1 (en) Glp-1 analogs useful for diabetes treatment
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
WO1999012561A3 (en) FRACTURE HEALING USING PTHrP ANALOGS
ATE305478T1 (de) Topoisomerase-ii inhibitoren
TH26711A (th) " สิ่งที่คล้ายกันของปัจจัยหลั่งฮอโมนของการเจริญเติบโต "

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0891378

Country of ref document: EP